Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amarin Corporation plc

< Previous 1 2 Next >
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Second Quarter 2023 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Appoints Patrick Holt as President and Chief Executive Officer
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Present at Two Upcoming Investor Conferences
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Board Departures
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN ASX CSLLY
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Present at Cowen's 43rd Annual Health Care Conference
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Urges Shareholders to Vote “Against” Sarissa’s Harmful Proposals at Upcoming General Meeting – IT HAS NO PLAN, NO NEW IDEAS AND AN UNDERQUALIFIED SLATE
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.